{"id":208,"date":"2023-02-15T15:50:44","date_gmt":"2023-02-15T15:50:44","guid":{"rendered":"http:\/\/192.168.10.30\/?page_id=208"},"modified":"2023-02-15T15:50:44","modified_gmt":"2023-02-15T15:50:44","slug":"concorde","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=208","title":{"rendered":"Concorde"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non-small cell lung cancer<\/p>\n\n\n\n

Trial summary:<\/h2>\n\n\n\n

To assess the safety and determine the recommended phase II dose (RP2D) of DNA damage response inhibitors (DDRi) to be used in combination with radical thoracic radiotherapy in stage IIB\/III non-small cell lung cancer (NSCLC). Five different inhibitors will be applied, each on a different study arm aiming to get approximately 30 patients in each experimental arm treated with DDRi + Radiotherapy and approximately 50-60 patients treated with RT alone. Total accrual is estimated to 210 patients in 6 years.<\/p>\n\n\n\n

RT QA summary:<\/h2>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td><\/td><\/td>\n<\/tr>\n
Planning Benchmark Case<\/td><\/td><\/td>\n<\/tr>\n
Dummy Run<\/td>\"\"<\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td><\/td><\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry <\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>ADSCAN, Isotoxic IMRT<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA contact:<\/strong> concordeqa.enh-tr@nhs.net<\/em><\/a> <\/p>\n\n\n\n

Chief investigator: <\/strong>Dr Alastair Greystoke \/ Dr Corinne Faivre-Finn<\/p>\n\n\n\n

Sponsor: <\/strong>University of Leeds \u00a0ctru_concorde@leeds.ac.uk<\/em><\/a><\/p>\n\n\n\n

Funder: <\/strong>CRUK, AstraZeneca<\/p>\n","protected":false},"excerpt":{"rendered":"

A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non-small cell lung cancer Trial summary: To assess […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-208","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=208"}],"version-history":[{"count":1,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/208\/revisions"}],"predecessor-version":[{"id":210,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/208\/revisions\/210"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}